透析患者血磷管理的现状与进展  

Phosphorus management in dialysis patients:current status and advances

作　　者：周洋(综述) 李贵森(审校) ZHOU Yang;LI Guisen(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,China;Department of Nephrology,Sichuan Academy of Medical Sciencs,Sichuan Provincial People s Hospital,Chengdu 610072,China)

机构地区：[1]电子科技大学医学院,成都610054 [2]四川省医学科学院·四川省人民医院肾脏内科

出　　处：《肾脏病与透析肾移植杂志》2025年第1期85-90,共6页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：国家自然科学基金联合基金重点支持项目(U21A20349);四川省中央引导地方科技发展专项项目(2023ZYD0170)。

摘　　要：慢性肾脏病矿物质和骨异常(CKD-MBD)是指慢性肾脏病所致的矿物质与骨代谢异常综合征,可累及心血管、骨组织,并最终引起全身多器官及系统损害,是患者死亡的重要原因。高磷血症为CKD-MBD的始动因素,故透析患者的血磷管理非常重要,但透析患者的血磷达标率并不高。近年来,根据发病机制,研发了一系列新型降磷药物,包括含铁磷结合剂、钙镁复合磷结合剂、烟酰胺等,还有一些正在进行临床试验的新型降磷药物。本文就透析患者血磷管理的现状,新型降磷药物的作用及特点作一综述。Chronic kidney disease-mineral and bone disorder(CKD-MBD)refers to a syndrome of mineral and bone metabolism abnormalities caused by chronic kidney disease.It can affect the cardiovascular system and bone tissue,eventually leading to damage to multiple organs and systems throughout the body,making it a significant cause of patient mortality.Hyperphosphatemia is the initiating factor of CKD-MBD,making the management of blood phosphorus levels in dialysis patients extremely important;however,the rate of achieving target blood phosphorus levels in these patients is not high.In recent years,a series of new phosphate-lowering drugs have been developed based on new mechanisms,including iron-based phosphate binders,calcium-magnesium composite phosphate binders,and niacinamide,among others.Additionally,there are some novel phosphate-lowering drugs undergoing clinical trials.This article reviews the current status of blood phosphorus management in dialysis patients and the effects and characteristics of these new phosphate-lowering drugs.

关 键 词：慢性肾脏病矿物质和骨异常 高磷血症 血液透析 降磷药物 

分 类 号：R69[医药卫生—泌尿科学]